Jeffrey Weber, MD, PhD, NYU Langone Health, Perlmutter Cancer Center

Articles

Rapids Readouts: Phase 3 CheckMate 238 Trial

October 30th 2020

Dr. Weber on Emerging Immunotherapy Combinations in Melanoma

February 19th 2020

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the melanoma program, Laura and Isaac Perlmutter Professor of Oncology, Department of Medicine, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses emerging immunotherapy combinations in melanoma.

Jeffrey Weber, MD, PhD: Charting New Territories in Melanoma

February 12th 2020

In our exclusive interview, Jeffrey S. Weber, MD, PhD, shares with us his journey into the melanoma field and the lessons he has learned along the way, some of the key studies that have significantly impacted his career and clinical practice, and what lies ahead in the melanoma pipeline.

Dr. Weber on Adjuvant Approaches in Stage III Melanoma

January 27th 2020

Jeffrey S. Weber, MD, PhD, discusses adjuvant approaches in stage III melanoma.

Dr. Weber on Adjuvant Pembrolizumab in Melanoma

November 23rd 2019

Jeffrey S. Weber, MD, PhD, discusses the phase III EORTC1325/KEYNOTE-054 trial, which looked at adjuvant pembrolizumab in patients with stage III melanoma.

Dr. Weber on Biomarker Data From CheckMate-238 for Melanoma

November 7th 2019

Jeffrey S. Weber, MD, PhD, discusses biomarker research in the CheckMate-238 trial looking at patients with resected stage III/IV melanoma.

Dr. Weber on the Future of Checkpoint Inhibitors in Melanoma

October 25th 2019

Jeffrey S. Weber, MD, PhD, discusses the future of checkpoint inhibitors in melanoma.

Dr. Weber on Toxicity Data From CheckMate-238 Trial in Melanoma

October 18th 2019

Jeffrey S. Weber, MD, PhD, shares toxicity data from the randomized, double-blind, phase III CheckMate-238 trial in resected stage III or IV melanoma.

Dr. Weber on Rationale for the CheckMate-238 Trial in Melanoma

October 8th 2019

Jeffrey S. Weber, MD, PhD, discusses the rationale behind the randomized, double-blind, phase III CheckMate-238 trial in resected stage III or IV melanoma.

Dr. Weber on the Updated Analysis of the CheckMate-238 Trial in Melanoma

September 28th 2019

Jeffrey S. Weber, MD, PhD, discusses the updated analysis of the phase III CheckMate-238 trial in patients with resected stage III/IV melanoma.

x